Haitai Biological (300683.SZ) invested company ZM-02 ophthalmic injection has been approved to initiate clinical trials.

According to a report from Zhitong Finance APP, Haite Biological (300683.SZ) announced that its affiliated company Zhongmou Medical Technology (Wuhan) Co., Ltd. (referred to as "Zhongmou Medical") has received the "Clinical Trial Approval Notification" issued by the National Medical Products Administration. The clinical trial application for its self-developed ZM-02 eye injection has been approved by the National Medical Products Administration, allowing the product to conduct clinical trials for the treatment of advanced retinitis pigmentosa.